FDA Panel Gets Varied Opinions on DTC Genomics
March 10, 2011
FDA Panel Gets Varied Opinions on DTC Genomics
The Molecular and Clinical Genetics Panel held a public meeting this week to discuss potential strategies for regulating some DTC genetic tests.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Seeking 510(k) Clearance for Genomic Testing Service, 23andMe Maintains Direct-to-Consumer Ethos
August 1, 2012 / Pharmacogenomics Reporter - DTC Genetics Services Hit Hard on the Hill as FDA Mulls Options
July 23, 2010 / GenomeWeb Daily News - FDA Warns Consumer Genomics Firms, Illumina on Selling Unapproved Dx Products
June 11, 2010 / GenomeWeb Daily News - 23andMe Submits Documents for 510(k) Clearance from FDA
July 30, 2012 / GenomeWeb Daily News - Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS
October 19, 2011 / Pharmacogenomics Reporter